IN8bio, Inc.(INAB)
Biotechnology
Cell Therapy (CAR-T, etc.)
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-05-07 | BIOS Fund II, LP 10% Owner | Purchase | +1,148,482 | +89.50%2,431,763 | N/A | N/A | View SEC filing | |
| 2025-05-07 | BIOS Fund III NT, LP 10% Owner | Purchase | +1,148,482 | +89.50%2,431,763 | N/A | N/A | View SEC filing | |
| 2024-10-11 | BIOS Fund III NT, LP 10% Owner | Purchase | +1,283,281 | +275.93%1,748,350.285 | N/A | N/A | View SEC filing | |
| 2024-10-11 | BIOS Fund II, LP 10% Owner | Purchase | +1,283,281 | +275.93%1,748,350.285 | N/A | N/A | View SEC filing | |
| 2024-10-08 | FAIRBAIRN EMILY Director | Purchase | +6,077,486 | +100.00%6,077,486 | N/A | N/A | View SEC filing | |
| 2023-12-14 | Cavu Management, LP 10% Owner | Purchase | +1,722,723 | +100.00%1,722,723 | N/A | N/A | View SEC filing | |
| 2023-12-14 | BIOS Fund II, LP 10% Owner | Purchase | +1,722,723 | +100.00%1,722,723 | N/A | N/A | View SEC filing | |
| 2023-09-15 | Graff Jeremy R. Director | Purchase | +2,500 | +100.00%2,500 | $0.95 | $2,375 | View SEC filing | |
| 2023-08-28 | McCall Patrick Chief Financial Officer | Purchase | +1,000 | +19.00%6,263 | $1.03 | $1,030 | View SEC filing | |
| 2023-08-28 | Ho William Tai-Wei President and CEO | Purchase | +23,800 | +1.03%2,339,545 | $1.05 | $24,990 | View SEC filing | |
| 2022-12-13 | Cavu Management, LP Director, 10% Owner | Purchase | +75,001 | -3.72%570,724 | $2.48 | $185,912 | View SEC filing | |
| 2022-12-13 | BIOS Fund II, LP Director, 10% Owner | Purchase | +75,001 | -3.72%570,724 | $2.48 | $185,912 | View SEC filing | |
| 2022-09-29 | BIOS Fund II, LP Director, 10% Owner | Purchase | +25,000 | -4.70%561,989 | $2.02 | $50,535 | View SEC filing | |
| 2022-09-29 | Cavu Management, LP Director, 10% Owner | Purchase | +25,000 | -4.70%561,989 | $2.02 | $50,535 | View SEC filing | |
| 2022-08-30 | BIOS Fund II, LP Director, 10% Owner | Purchase | +51,214 | -4.17%559,076 | $2.02 | $103,340 | View SEC filing | |
| 2022-08-30 | BIOS Fund II, LP Director, 10% Owner | Purchase | +51,214 | -4.17%559,076 | $2.02 | $103,340 | View SEC filing | |
| 2022-08-18 | FAIRBAIRN EMILY Director, 10% Owner | Purchase | +789,473 | +23.76%4,111,958 | $1.90 | $1,499,999 | View SEC filing | |
| 2022-08-18 | Ho William Tai-Wei President, CEO and CFO | Purchase | +26,315 | +1.15%2,315,745 | $1.90 | $49,999 | View SEC filing | |
| 2022-08-18 | Rochlin Kate Chief Operating Officer | Purchase | +5,263 | +100.00%5,263 | $1.90 | $10,000 | View SEC filing | |
| 2022-08-18 | McCall Patrick Chief Financial Officer | Purchase | +5,263 | +100.00%5,263 | $1.90 | $10,000 | View SEC filing | |
| 2022-08-18 | Goswami Trishna Chief Medical Officer | Purchase | +2,631 | +100.00%2,631 | $1.90 | $4,999 | View SEC filing | |
| 2022-08-18 | Lamb Lawrence EVP and CSO | Purchase | +526 | +0.53%99,730 | $1.90 | $999 | View SEC filing | |
| 2022-08-18 | Greenwood Luba Director | Purchase | +526 | +7.21%7,826 | $1.90 | $999 | View SEC filing | |
| 2022-08-18 | Roemer Alan S. Director | Purchase | +26,315 | +88.68%55,989 | $1.90 | $49,999 | View SEC filing | |
| 2022-08-18 | Brandt Peter C. Director | Purchase | +105,263 | +136.33%182,473 | $1.90 | $200,000 | View SEC filing |
1-25 of 30